Related Experiment Video

Updated: Dec 29, 2025

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

263

The miRNAs Role in Melanoma and in Its Resistance to Therapy

Francesca Varrone1, Emilia Caputo2

  • 1IRBM S.p.A., Via Pontina Km 30,600, I-00071 Pomezia, Italy.

International Journal of Molecular Sciences
|February 5, 2020
PubMed

Insights

Melanoma microRNAs (miRNAs) show dual roles as oncogenic or tumor suppressive factors. Understanding these melanoma-associated miRNAs is crucial for developing novel treatments and overcoming drug resistance in this malignant skin cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Melanoma is an aggressive skin cancer with poor survival rates for metastatic disease.
  • Current treatments, including targeted therapies and immunotherapies, offer improved survival but challenges remain.
  • Melanoma-associated microRNAs (miRNAs) are emerging as critical players in melanoma progression and treatment response.

Purpose of the Study:

  • To review the current data on melanoma-associated miRNAs.
  • To explore the role of miRNAs in melanoma drug resistance.
  • To discuss the potential of miRNAs as prognostic factors and therapeutic targets.

Main Methods:

  • Literature review of recent studies on melanoma-associated miRNAs.
  • Analysis of miRNA involvement in melanoma progression and drug resistance.
  • Evaluation of miRNA stability and prognostic potential.

Main Results:

  • Melanoma-associated miRNAs exhibit a dual role, acting as either oncogenic or tumor suppressive factors.
  • miRNAs are implicated in the development of drug resistance in melanoma.
  • The stability and conserved nature of miRNAs make them promising prognostic indicators.

Conclusions:

  • Melanoma-associated miRNAs represent a significant area for novel therapeutic strategies.
  • Targeting miRNAs could offer new avenues to overcome drug resistance and improve melanoma patient outcomes.
  • Further research into the specific functions and targets of these miRNAs is warranted.
Keywords:
drug resistancemelanomametastasismiRNAs

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K